Metabolic syndrome is an aggregate of altered metabolic and biochemical phenomena, precipitating in diabetes, obesity, dyslipidemia, and cardiovascular diseases. Their diagnosis and treatment should be initiated early to prevent their worsening. The current chapter reviews PubMed, Scopus, and Elsevier databases on the latest scientific approaches in nanosensors and nanotherapeutics in metabolic syndrome. The research articles are past 2020, and the recent works are focused. Hyperglycemia and obesity are increasing at an alarming rate primarily due to sedentary lifestyles, high-fat diets, and calorie-rich foods, which are preventable. Dyslipidemia is slowly engulfing with its consequences and is one of the primary causes of atherosclerosis, plaque formation, and other cardiovascular diseases. Obesity can lead to diabetes, dyslipidemia, and cardiovascular symptoms. The design of robust, precise, reusable, specific, sensitive, and accurate nanosensors will minimize the burden of metabolic syndrome, afflicting the majority of the population globally. However, the role of nanosensors is limited to detection of the condition. Nanotherapeutics offers versatile opportunities for designing novel therapeutic platforms for diabetes, obesity, and dyslipidemia. The therapeutic delivery systems promise superior efficiency, minimally invasive or noninvasive techniques, and cost-effectiveness. They promote controlled and sustained drug release with drugs of varying physicochemical properties. But nanotechnology might provide benchmark therapeutic novelties in metabolic syndrome management, only after human clinical trials are completed. Scale-up and regulatory approval are mandatory requirements for their commercialization. No study on metabolic syndrome has been done on humans. Thus, the ultimate challenge of nanosensors and nanotherapeutics for metabolic syndrome is far ahead, and the future scope lies in maximizing their use and benefits for clinical applications in humans.